FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028654847> ?p ?o ?g. }

• W2028654847 abstract "ABSTRACT Aim: The optimal duration of treatment for patients with metastatic colorectal cancer is still under debate. Maintenance therapy after induction chemotherapy is an increasingly used therapeutic option. Methods: A systematic review of MEDLINE, EMBASE and Cochrane Systematic reviews databases from January 1966 to May 2014 was performed independently by two Authors. All randomized phase III trials comparing maintenance Bevacizumab or capecitabine plus bevacizumab versus other therapeutic strategies were considered eligible and included into the analysis. The 3-years Overall survival was the primary outcome of the analysis; 1 years OS, 2 years OS, 3 years PFS, 2 years PFS and 1 years PFS were secondary ones. Heterogeneity between the trials was assessed using the Mantel-Haenszel test, and the pooled Odds Ratios (ORs) were calculated using a fixed effects model. An alpha error Results: 681 patients of two trials and 738 patients of two trials were included into the two different analysis. A significant improvement in PFS at 12 months (OR 0,67 IC 95% 0,5-0,92; p = 0,01) and OS at 36 months (OR 0,62 IC 95% 0,4-0,98; p= 0,04) were observed in subgroup with maintenance therapy with capecitabine + Bevacizumab versus other therapeutic strategies (stop and go therapy and continuous therapy). No differences were observed in OS at 36 months (OR 0,66 IC95% 0,42-1,04; p = 0,07) and PFS at 12 months (OR 0,89 IC95% 0,64-1,24; p = 0,5) in the subgroup analysis with Bevacizumab only maintenance therapy versus other therapeutic strategies. 12 months 24 months 36 months OS (overall population) OR 0,92 (IC 0,73-1,17; p = 0,51) OR 0,91 (IC 0,73-1,13; p = 0,39) OR 0,64 (IC 0,47-0,88; p = 0,006) OS (subgroup cape + Bev) OR 0,62 (IC 0,4-0,98; p= 0,04) OS (Subgroup Bev only) OR 0,66 (IC 0,42-1,04; p = 0,07) PFS (overall population) OR 0,77 (IC 0,62-0,96; p = 0,02) PFS(subgroup cape + Bev) OR 0,67 (IC 0,5-0,92; p = 0,01) PFS(subgroup Bev only) OR 0,89 (IC 0,64-1,24; p = 0,5) Conclusions: Our data confirm that maintenance therapy is a effectiveness therapeutic option. Despite this, the standard regimen in the maintenance setting remains unclear. Trials included into the analysis suggest that fluoropyrimidine is a key for effectiveness of maintenance treatment. Further studies comparing Bevacizumab vs fluoropyrimidine + Bevacizumab vs fluoropyrimidine alone is needed to evaluated the gold standard in this setting of therapy. Disclosure: All authors have declared no conflicts of interest." @default.
• W2028654847 created "2016-06-24" @default.
• W2028654847 creator A5008636632 @default.
• W2028654847 creator A5010804802 @default.
• W2028654847 creator A5019332793 @default.
• W2028654847 creator A5021193801 @default.
• W2028654847 creator A5030458305 @default.
• W2028654847 creator A5060683338 @default.
• W2028654847 creator A5068161307 @default.
• W2028654847 creator A5077437284 @default.
• W2028654847 creator A5079653995 @default.
• W2028654847 creator A5088944331 @default.
• W2028654847 creator A5091286114 @default.
• W2028654847 creator A5091856899 @default.
• W2028654847 date "2014-06-01" @default.
• W2028654847 modified "2023-09-30" @default.
• W2028654847 title "Maintenance Bevacizumab After Induction Chemotherapy: Systematic Review of Literature and Pooled Analysis of Randomized Clinical Trials" @default.
• W2028654847 doi "https://doi.org/10.1093/annonc/mdu165.202" @default.
• W2028654847 hasPublicationYear "2014" @default.
• W2028654847 type Work @default.
• W2028654847 sameAs 2028654847 @default.
• W2028654847 citedByCount "0" @default.
• W2028654847 crossrefType "journal-article" @default.
• W2028654847 hasAuthorship W2028654847A5008636632 @default.
• W2028654847 hasAuthorship W2028654847A5010804802 @default.
• W2028654847 hasAuthorship W2028654847A5019332793 @default.
• W2028654847 hasAuthorship W2028654847A5021193801 @default.
• W2028654847 hasAuthorship W2028654847A5030458305 @default.
• W2028654847 hasAuthorship W2028654847A5060683338 @default.
• W2028654847 hasAuthorship W2028654847A5068161307 @default.
• W2028654847 hasAuthorship W2028654847A5077437284 @default.
• W2028654847 hasAuthorship W2028654847A5079653995 @default.
• W2028654847 hasAuthorship W2028654847A5088944331 @default.
• W2028654847 hasAuthorship W2028654847A5091286114 @default.
• W2028654847 hasAuthorship W2028654847A5091856899 @default.
• W2028654847 hasBestOaLocation W20286548471 @default.
• W2028654847 hasConcept C121608353 @default.
• W2028654847 hasConcept C126322002 @default.
• W2028654847 hasConcept C141071460 @default.
• W2028654847 hasConcept C143998085 @default.
• W2028654847 hasConcept C156957248 @default.
• W2028654847 hasConcept C168563851 @default.
• W2028654847 hasConcept C187960798 @default.
• W2028654847 hasConcept C2776478404 @default.
• W2028654847 hasConcept C2776694085 @default.
• W2028654847 hasConcept C2777802072 @default.
• W2028654847 hasConcept C2777909004 @default.
• W2028654847 hasConcept C2778283404 @default.
• W2028654847 hasConcept C2780739268 @default.
• W2028654847 hasConcept C526805850 @default.
• W2028654847 hasConcept C71924100 @default.
• W2028654847 hasConcept C95190672 @default.
• W2028654847 hasConceptScore W2028654847C121608353 @default.
• W2028654847 hasConceptScore W2028654847C126322002 @default.
• W2028654847 hasConceptScore W2028654847C141071460 @default.
• W2028654847 hasConceptScore W2028654847C143998085 @default.
• W2028654847 hasConceptScore W2028654847C156957248 @default.
• W2028654847 hasConceptScore W2028654847C168563851 @default.
• W2028654847 hasConceptScore W2028654847C187960798 @default.
• W2028654847 hasConceptScore W2028654847C2776478404 @default.
• W2028654847 hasConceptScore W2028654847C2776694085 @default.
• W2028654847 hasConceptScore W2028654847C2777802072 @default.
• W2028654847 hasConceptScore W2028654847C2777909004 @default.
• W2028654847 hasConceptScore W2028654847C2778283404 @default.
• W2028654847 hasConceptScore W2028654847C2780739268 @default.
• W2028654847 hasConceptScore W2028654847C526805850 @default.
• W2028654847 hasConceptScore W2028654847C71924100 @default.
• W2028654847 hasConceptScore W2028654847C95190672 @default.
• W2028654847 hasLocation W20286548471 @default.
• W2028654847 hasOpenAccess W2028654847 @default.
• W2028654847 hasPrimaryLocation W20286548471 @default.
• W2028654847 hasRelatedWork W2144159497 @default.
• W2028654847 hasRelatedWork W2224689257 @default.
• W2028654847 hasRelatedWork W2330350802 @default.
• W2028654847 hasRelatedWork W2517864759 @default.
• W2028654847 hasRelatedWork W2557007274 @default.
• W2028654847 hasRelatedWork W2775036676 @default.
• W2028654847 hasRelatedWork W2804337541 @default.
• W2028654847 hasRelatedWork W2805273862 @default.
• W2028654847 hasRelatedWork W2898379137 @default.
• W2028654847 hasRelatedWork W2901082418 @default.
• W2028654847 hasRelatedWork W2953682493 @default.
• W2028654847 hasRelatedWork W2969350423 @default.
• W2028654847 hasRelatedWork W2995315963 @default.
• W2028654847 hasRelatedWork W2996637695 @default.
• W2028654847 hasRelatedWork W2999270520 @default.
• W2028654847 hasRelatedWork W3002231793 @default.
• W2028654847 hasRelatedWork W3004966710 @default.
• W2028654847 hasRelatedWork W3128685317 @default.
• W2028654847 hasRelatedWork W3150599205 @default.
• W2028654847 hasRelatedWork W3156653656 @default.
• W2028654847 isParatext "false" @default.
• W2028654847 isRetracted "false" @default.
• W2028654847 magId "2028654847" @default.
• W2028654847 workType "article" @default.